• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Marillyn Hewson Joins Chevron’s Board of Directors

    12/2/20 4:30:00 PM ET
    $JNJ
    $CVX
    $LMT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Integrated oil Companies
    Energy
    Get the next $JNJ alert in real time by email

    SAN RAMON, Calif.--(BUSINESS WIRE)--Chevron Corporation (NYSE: CVX) announced that Marillyn A. Hewson has been elected to Chevron’s board of directors, effective on January 1, 2021. She will serve on the Audit Committee of the Board.

    Hewson, 66, is executive chairman of Lockheed Martin Corporation. She served as Lockheed Martin’s chairman, president and chief executive officer from January 2014 to June 2020 and held the positions of president and chief executive officer from January 2013 to December 2013.

    “It’s truly an honor to welcome Marillyn to Chevron’s board,” said Chevron Chairman and CEO Michael Wirth. “Marillyn is one of the world’s most accomplished business leaders. She brings valuable global business experience as well as decades of perspective on international commerce and geopolitics to our board, and will make our company better.”

    Hewson joined Lockheed Martin more than 35 years ago as an industrial engineer. During her career she has held leadership positions across the corporation. She currently serves on the board of directors of Johnson & Johnson, the Congressional Medal of Honor Foundation, the Board of Governors of the USO, and as chair of the Catalyst Board of Directors. Hewson has served on several U.S. government advisory bodies, including her current appointment to the American Workforce Policy Advisory Board. She earned her Bachelor of Science degree in business administration and her Master of Arts degree in economics from The University of Alabama and has completed executive development programs at Columbia Business School and Harvard Business School.

    Chevron Corporation is one of the world’s leading integrated energy companies. Through its subsidiaries that conduct business worldwide, the company is involved in virtually every facet of the energy industry. Chevron explores for, produces and transports crude oil and natural gas; refines, markets and distributes transportation fuels and lubricants; manufactures and sells petrochemicals and additives; generates power; and develops and deploys technologies that enhance business value in every aspect of the company’s operations. Chevron is based in San Ramon, Calif. More information about Chevron is available at www.chevron.com.

    Get the next $JNJ alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $JNJ
    $CVX
    $LMT

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Chevron Corporation
    $CVX
    5/13/2025$158.00Buy → Hold
    HSBC Securities
    Chevron Corporation
    $CVX
    5/6/2025$130.00Buy → Sell
    DZ Bank
    Chevron Corporation
    $CVX
    5/5/2025$155.00 → $150.00Hold
    TD Cowen
    Chevron Corporation
    $CVX
    4/23/2025$124.00Neutral → Sell
    Redburn Atlantic
    Lockheed Martin Corporation
    $LMT
    4/23/2025$540.00Neutral → Outperform
    Robert W. Baird
    Chevron Corporation
    $CVX
    4/23/2025$171.00 → $152.00Overweight → Equal Weight
    Barclays
    Lockheed Martin Corporation
    $LMT
    4/16/2025$575.00Equal-Weight → Overweight
    Morgan Stanley
    More analyst ratings

    $JNJ
    $CVX
    $LMT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Hewson Marillyn A

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:32:25 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Woods Eugene A.

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      6/12/25 4:30:37 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Booth Thomas Ryder claimed ownership of 3,181 shares (SEC Form 3)

      3 - CHEVRON CORP (0000093410) (Issuer)

      6/9/25 4:54:11 PM ET
      $CVX
      Integrated oil Companies
      Energy

    $JNJ
    $CVX
    $LMT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • July 21, 2023 - FDA Roundup: July 21, 2023

      For Immediate Release: July 21, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA Center for Tobacco Products (CTP) announced that the center will host a virtual listening session on Aug. 22, 2023. During this listening session, CTP is requesting feedback on the development of a new 5-year strategic plan for the center, includin

      7/21/23 4:02:23 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • May 5, 2022 - Coronavirus (COVID-19) Update: FDA Limits Use of Janssen COVID-19 Vaccine to Certain Individuals

      For Immediate Release: May 05, 2022 Today, the U.S. Food and Drug Administration has limited the authorized use of the Janssen COVID-19 Vaccine to individuals 18 years of age and older for whom other authorized or approved COVID-19 vaccines are not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Janssen COVID-19 Vaccine because they would otherwise not

      5/5/22 4:51:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • August 18, 2021 - Joint Statement from HHS Public Health and Medical Experts on COVID-19 Booster Shots

      For Immediate Release: August 18, 2021 Today, public health and medical experts from the U.S. Department of Health and Human Services (HHS) released the following statement on the Administration’s plan for COVID-19 booster shots for the American people. The statement is attributable to Dr. Rochelle Walensky, Director of the Centers for Disease Control and Prevention (CDC); Dr. Janet Woodcock, Acting Commissione

      8/18/21 1:06:11 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $JNJ
    $CVX
    $LMT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Johnson & Johnson downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Johnson & Johnson from Outperform to Market Perform and set a new price target of $153.00

      5/13/25 8:56:13 AM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chevron downgraded by HSBC Securities with a new price target

      HSBC Securities downgraded Chevron from Buy to Hold and set a new price target of $158.00

      5/13/25 8:52:41 AM ET
      $CVX
      Integrated oil Companies
      Energy
    • Chevron downgraded by DZ Bank with a new price target

      DZ Bank downgraded Chevron from Buy to Sell and set a new price target of $130.00

      5/6/25 8:02:15 AM ET
      $CVX
      Integrated oil Companies
      Energy

    $JNJ
    $CVX
    $LMT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

      4 - JOHNSON & JOHNSON (0000200406) (Issuer)

      12/12/24 5:27:36 PM ET
      $JNJ
      Biotechnology: Pharmaceutical Preparations
      Health Care